A group of technicians diligently working in a laboratory

Medicines in Development

Patients with a wide range of life-threatening and debilitating illnesses today live in the hope tomorrow will bring a new medicine that will improve or even save their life. America’s biopharmaceutical research companies are researching and developing new medicines to meet unmet need and continuing research and development even after U.S. Food and Drug Administration (FDA) approval, all with the goal of improving patients’ health, quality of life, and saving lives.

Since 2000, nearly 900 new medicines have been approved by the FDA, helping patients live longer, healthier lives. Among the remarkable new treatments reaching patients are the first gene therapies for devastating rare genetic disorders impacting infants and children, curative treatments for hepatitis C, a range of CAR-T cell therapies driving unprecedented remission rates for cancer patients as well as immunotherapies and targeted therapies widely regarded as driving accelerated drops in cancer mortality for U.S. patients in recent years.

Explore the medicines in development for a wide range of diseases below.

Medicines in Development 2022 Report: Disorders of the Blood 

Young patient having his arm swabbed by a doctor

Read about the more than 500 medicines, treating many of the diseases and conditions that affect the blood, that are currently in development by the America’s biopharmaceutical research companies.

Young patient having his arm swabbed by a doctor

Female doctor wearing a stethoscope and pointing at a clipboard with a pen, talking with a female patient

-

Report

Medicines in Development for Women's Health 2022 Report

Read about the more than 600 medicines and vaccines, treating many of the diseases and conditions of particular concern for women's health, that are currently in development by the America's biopharmaceutical research companies.

Biopharmaceutical researcher wearing protective gear and working at a laptop, with lab equipment surrounding

-

Report

Medicines in Development for Rare Diseases 2021 Report

Read about the more than 700 medicines and vaccines, treating many of the approximately 8,000 known rare diseases, that are currently in development by the America's biopharmaceutical research companies.

Teaser image featuring the first page of PhRMA's report on 2021 Medicines in Development for Neurodegenerative Diseases

-

Report

Medicines in Development for Neurodegenerative Diseases 2021 Report

Today, more than 260 medicines and vaccines for 29 different neurodegenerative diseases are currently in development by innovative biopharmaceutical research companies.

A teaser image of the first page of PhRMA's 2021 Medicines in Development for Health Equity report

-

Report

Medicines in Development for Health Equity 2021 Report

Today, more than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities.

A teaser image of the Medicines in Development for Antimicrobial Resistance for 2021 Report, from PhRMA

-

Report

Medicines in Development for Antimicrobial Resistance 2021 Report

As the world confronts the COVID-19 public health crisis, now more than ever is the time to consider preparedness for a growing public health threat: antimicrobial resistance (AMR). This means a robust and sustained pipeline of new and novel antimicrobial medicines is critical to ensure that new innovations and interventions can keep pace with these evolving pathogens.

A teaser image of the 2020 PhRMA Medicines in Development for Cancer Report

-

Report

Medicines in Development for Cancer 2020 Report

Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA).

-

Report

Medicines in Development for Infectious Diseases 2020 Report

More than 400 medicines and vaccines are in development to tackle infectious diseases.

-

Report

Medicines in Development for Vaccines 2020 Report

Over the years, vaccines have played a critical role in reducing the spread of, and, in some cases, eliminating the threat of the world’s many devastating infectious diseases. Vaccines represent some of the most impactful public health advances seen to date.

-

Report

Medicines in Development for Cell and Gene Therapy 2020

Nearly 400 cell and gene therapies are in development, targeting a broad range of diseases.

-

Report

Medicines in Development for Children 2020 Report

The biopharmaceutical industry is currently developing nearly 600 medicines to meed the unique needs of pediatric patients.

-

Report

Medicines in Development for Mental Illness 2019 Report

Biopharmaceutical Research Companies Are Developing 138 Medicines to Treat Mental Illness

-

Report

Medicines in Development for Cell and Gene Therapy 2018 Report

Nearly 300 cell and gene therapies in development for a broad range of diseases.

-

Report

Medicines in Development for Skin Diseases 2018 Update

More than 300 medicines to treat skin diseases are in development by biopharmaceutical research companies.

-

Report

Medicines in Development for Heart Disease and Stroke 2018 Report

America’s biopharmaceutical research companies are developing 200 medicines for leading causes of death in the U.S.

MID-neuro-drug-list-lg1

-

Report

Medicines in Development for Neurological Disorders 2018 Report

America's biopharmaceutical companies are developing 537 medicines for numerous, wide-ranging neurological disorders.

-

Report

Medicines in Development for Alzheimer's Disease 2017 Report

America’s biopharmaceutical research companies are investigating or developing 85 medicines for Alzheimer's.

-

Report

Medicines in Development for HIV 2017 Report

America’s biopharmaceutical research companies are developing 52 medicines and vaccines for HIV.

-

Report

Medicines in Development for Immuno-Oncology 2017 Report

America’s biopharmaceutical research companies are developing more than 240 immuno-oncology treatments.

-

Report

Medicines in Development for Vaccines 2017 Update

America’s biopharmaceutical research companies are developing more than 260 vaccines. 

-

Report

Medicines in Development for Autoimmune Diseases 2016 Report

America’s biopharmaceutical research companies are investigating or developing 80 medicines for autoimmune diseases.

-

Report

Medicines in Development for Osteoporosis 2016 Report

America's biopharmaceutical research companies are developing nine medicines for the treatment of osteoporosis.

-

Report

Medicines in Development for Rare Diseases 2016 Report

America's biopharmaceutical research companies are developing 566 medicines for patients with rare diseases.

-

Report

Medicines in Development for Leukemia & Lymphoma 2015 Report

America’s biopharmaceutical research companies are developing more than 240 medicines for leukemia, lymphoma and other blood cancers.

Parkinsons

-

Report

Medicines in Development for Parkinson's Disease 2014 Report

America’s biopharmaceutical research companies are currently developing 37 medicines to help the estimated 1.5 million Americans living with Parkinson’s Disease.

-

Report

Medicines in Development for Biologics 2013 Report

America’s biopharmaceutical research companies are developing 907 biologics targeting more than 100 diseases.

Breast Cancer

-

Report

Medicines in Development for Women 2013 Report

America's biopharmaceutical research companies are developing 851 medicines for diseases that affect American women.

-

Report

Medicines in Development for COPD 2012 Report

America’s biopharmaceutical research companies are working on 54 medicines to treat chronic obstructive pulmonary disease (COPD).